{"id":662670,"date":"2026-08-29T20:37:15","date_gmt":"2026-08-29T20:37:15","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/662670\/"},"modified":"2026-08-29T20:37:15","modified_gmt":"2026-08-29T20:37:15","slug":"can-dupilumab-boost-growth-in-kids-with-severe-eczema","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/662670\/","title":{"rendered":"Can Dupilumab Boost Growth in Kids With Severe Eczema?"},"content":{"rendered":"

Treatment with dupilumab (Dupixent, Sanofi & Regeneron) may boost growth in kids with severe eczema, finds new research<\/a> in the Journal of the American Academy of Dermatology.<\/p>\n

The study of 123 children focused on growth and a biomarker of mineralization bone alkaline phosphatase (BALP) in 6- to 11-year-olds with severe eczema.<\/p>\n

The main takeaway? Children who had severe eczema and growth restriction and received dupilumab grew more than those with similar eczema and growth restriction who did not receive the treatment, report researchers who were led by Alan Irvine, MD,<\/strong> Professor of Dermatology in Trinity\u2019s School of Medicine in Dublin, Ireland. The new study was a post hoc analysis of a Phase 3 randomized, placebo-controlled clinical trial and an open-label extension study.<\/p>\n

When researchers analyzed data from the original clinical trial, the team found that children who had severe eczema were, on average, shorter than population norms.<\/p>\n

When their growth was tracked through the clinical trials, it was clear that those who were most growth-restricted benefited greatly from dupilumab treatment, with significant increases in height over the first 16 weeks of the trial.<\/p>\n

After 16 weeks, the group that had been given a placebo was switched to dupilumab, and the children, too, rapidly caught up in growth. Blood markers that measure new bone growth also reflected normal growth, the study found.<\/p>\n

\u201cChildren who live with severe eczema often have delayed growth that is poorly understood but is thought to be due to a combination of factors, including the energy needed to maintain inflammation, sleep disruption and possibly the effects of steroid treatments for the condition,\u201d says Dr. Irvine in a news release.<\/p>\n

\u201cThese findings are good news for children living with eczema. Effective treatment of eczema not only improves the skin, but it may also help children grow at a more normal rate and support healthy bone development.\u201d<\/p>\n

Exactly what is driving the improved growth in these kids is not fully understood yet, he says. \u201cIt may be that reducing chronic inflammation helps the body grow, or it may be because better sleep, thanks to improved itch, supports growth. Further research is needed to understand the mechanisms at play.\u201d<\/p>\n


\n \"Print
\n <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Treatment with dupilumab (Dupixent, Sanofi & Regeneron) may boost growth in kids with severe eczema, finds new research…\n","protected":false},"author":2,"featured_media":662671,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[78],"tags":[10306,34975,32899,18,135,19,17,279974],"class_list":["post-662670","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-atopic-dermatitis","tag-dupilumab","tag-eczema","tag-eire","tag-health","tag-ie","tag-ireland","tag-pediatric-atopic-dermatitis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/117180724645474326","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/662670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=662670"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/662670\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/662671"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=662670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=662670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=662670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}